MWNA
NVCR icon

Marshall Wace North America’s NovoCure NVCR Stock Holding History

Marshall Wace North America’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,860
Closed -$96K – 1793
2018
Q4 		$96K Buy
+2,860
New +$105K ﹤0.01% 1090
2017
Q4 		– Sell
-207,591
Closed -$4.15M – 1536
2017
Q3 		$4.15M Buy
+207,591
New +$4.08M 0.03% 597

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Marshall Wace North America's NVCR Position: Q1 2019 in Review

Marshall Wace North America sold out of NovoCure (NVCR) in Q1 2019, closing a stake of 2,860 shares — an estimated $96K sold.

Marshall Wace North America first reported a position in NVCR in Q3 2017 and held it in 2 quarters. The position peaked at $4.15M in Q3 2017. 200 funds tracked by Wall St. Rank hold NVCR as of Q1 2019.

  • Marshall Wace North America reported no remaining NovoCure position as of Q1 2019 after selling out during the quarter.
  • Marshall Wace North America sold 2,860 NovoCure shares in Q1 2019, an estimated $96K.
  • Marshall Wace North America first reported a position in NovoCure in Q3 2017 and held it in 2 quarters.
  • Marshall Wace North America's NovoCure position peaked at $4.15M in Q3 2017.
  • 200 funds tracked by Wall St. Rank held NovoCure as of Q1 2019.

Based on Marshall Wace North America's 13F filing for Q1 2019, filed 14 May 2019.